Protocols · MSK/Tissue Repair
BPC-157 + TB-500 Soft Tissue Repair Stack
Regenerative Stack | Soft Tissue & Tendon Repair
Typical Dose
250mcg BPC + 2.5mg TB
BPC-157 SC BID; TB-500 SC twice weekly during loading
Route
Subcutaneous
Inject as close to injury site as anatomically practical
Cycle
8–12 weeks
Loading 4wk → consolidation 4wk → taper 4wk
Storage
Refrigerate 2–8°C
Reconstituted vials stable ~30 days refrigerated; protect from light
Patient version available. Share ?view=patient with patients for the plain-language handout.
Overview
The BPC-157 + TB-500 stack is the most frequently deployed peptide combination in regenerative MSK practice, targeting patients with chronic tendinopathy, ligamentous injury, post-surgical tissue remodeling, muscle strains, and overuse syndromes refractory to conventional rehab. The protocol is designed to accelerate the proliferative and remodeling phases of tissue healing while reducing the chronic low-grade inflammation that perpetuates recalcitrant soft-tissue pathology.
Typical candidates include athletes with chronic tendinopathy (Achilles, patellar, lateral epicondyle), post-operative orthopedic patients (rotator cuff, ACL, meniscal repair), patients with persistent ligament sprains, and individuals with chronic muscle injuries or fascial adhesions. The stack is also used adjunctively in connective tissue conditions where collagen turnover and angiogenesis are limiting factors in recovery.
Functionally, BPC-157 drives local cytoprotection, angiogenesis, and fibroblast recruitment, while TB-500 (a synthetic fragment of Thymosin Beta-4) acts more systemically to promote actin sequestration, cell migration, and modulation of inflammatory cytokines. Together they address both the local repair microenvironment and the systemic substrate for tissue remodeling.
Key Benefits
Accelerates tendon, ligament, and muscle repair while reducing chronic inflammation in refractory soft-tissue injuries. Most-prescribed combination for post-surgical recovery and chronic tendinopathy.
Mechanism of Action
BPC-157 drives local angiogenesis (VEGFR2) and fibroblast recruitment; TB-500 sequesters G-actin to enable cell migration and progenitor mobilization. Convergent suppression of TGF-β–mediated fibrosis.
Research Indications
Chronic TendinopathyEFFECTIVE
Achilles / Patellar / Lateral Epicondyle
Improves fibrillar pattern on US; reduces VAS pain 20–40% by week 4 in compliant patients.
Refractory to Conservative Care
Target population is rehab-resistant tendinopathy where vascularity and collagen turnover are rate-limiting.
Post-Surgical RecoveryEFFECTIVE
Rotator Cuff / ACL / Meniscal Repair
Accelerates proliferative and remodeling phases; reduces scar tissue formation.
Timing
Begin BPC-157 24–72h post-op once hemostasis confirmed; delay TB-500 to day 5–7.
Ligament & Muscle InjuryEFFECTIVE
Persistent Sprains
Supports collagen organization and microvascular perfusion in poorly vascularized tissue.
Muscle Strains / Fascial Adhesions
TB-500 drives progenitor cell recruitment; BPC drives local fibroblast response.
Overuse SyndromesEMERGING
Athletic Populations
Used adjunctively when chronic low-grade inflammation perpetuates recalcitrant pathology.
Connective Tissue Conditions
Adjunct where collagen turnover and angiogenesis are limiting factors.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Loading (Wk 1–4) BPC-157 | 250mcg | BID | SC near injury |
| Loading (Wk 1–4) TB-500 | 2.5mg | Twice weekly | SC |
| Consolidation (Wk 5–8) BPC-157 | 250–500mcg | Once daily | SC |
| Consolidation (Wk 5–8) TB-500 | 2.5mg | Once weekly | SC |
| Taper (Wk 9–12) BPC-157 | 250mcg | 5 days/week | SC |
| Taper (Wk 9–12) TB-500 | 2.0–2.5mg | Every 10–14 days | SC |
| Post-Surgical Variant | Standard loading doses | BPC at 24–72h post-op; TB-500 at day 5–7 | SC |
Timing · Inject BPC-157 as close to the target tissue as anatomically practical. TB-500 effect is systemic — site is less critical. Coordinate post-surgical timing with the operating surgeon. Cycles beyond 6 months lack safety data.
Peptide Interactions
- GHK-Cu— Complementary collagen remodeling and angiogenic signaling.SYNERGISTIC
- CJC-1295 / Ipamorelin— GH/IGF-1 axis supports tissue substrate; monitor IGF-1 if combined.SYNERGISTIC
- Tesamorelin— No known interaction; may support recovery substrate.COMPATIBLE
- PT-141— No mechanistic overlap.COMPATIBLE
- Semaglutide / Tirzepatide— GLP-1 agonists may slow tissue perfusion via reduced caloric intake; ensure adequate protein/nutrition during repair.MONITOR
- Anticoagulants (warfarin, DOACs)— Theoretical additive effect given angiogenic activity; not a true peptide but clinically relevant.MONITOR
- NSAIDs— May blunt the proliferative phase of healing; minimize during active dosing where feasible.AVOID
How to Reconstitute
- 1
Gather supplies: BPC-157 10mg vial, TB-500 10mg vial (or 20mg combo), bacteriostatic water, alcohol swabs, insulin syringes.
- 2
Allow lyophilized vials to reach room temperature for 10–15 minutes before reconstitution.
- 3
Swab the rubber stopper of each peptide vial and the BAC water vial with isopropyl alcohol.
- 4
For BPC-157 10mg: draw 2.0mL bacteriostatic water (yields 250mcg per 5 units on an insulin syringe).
- 5
Inject the diluent slowly down the inside wall of the BPC-157 vial — do not force directly onto the powder.
- 6
For TB-500 10mg: draw 2.0mL bacteriostatic water (yields 2.5mg per 50 units on an insulin syringe).
- 7
Repeat slow-wall injection technique for the TB-500 vial.
- 8
Gently swirl each vial — do not shake. Allow 1–2 minutes for full dissolution; solution should be clear and colorless.
- 9
Label both vials with peptide name, concentration, reconstitution date, and discard date (30 days).
- 10
Store reconstituted vials refrigerated at 2–8°C, protected from light.
- 11
For each injection: swab stopper, draw appropriate units, expel air, swab injection site, inject SC at 45–90° into subcutaneous tissue.
- 12
Rotate injection sites; for BPC-157 prefer sites near or proximal to the target injury.
Quality Indicators
Clear, Colorless Solution
Properly reconstituted peptide should be transparent with no visible particulate.
Full Dissolution
Powder dissolves completely within 1–2 minutes of gentle swirling.
Slight Cloudiness After Cold Storage
May resolve at room temperature; if persistent, discard.
Discoloration or Particulate
Yellow tint, visible particles, or precipitate indicates degradation — discard.
Foaming on Reconstitution
Indicates over-vigorous mixing and peptide denaturation.
What to Expect
Weeks 1–2: possible transient fatigue or mild flu-like malaise from TB-500; mild flushing or lightheadedness from BPC-157.
Week 4: subjective pain reduction of 20–40% on VAS, decreased morning stiffness, improved tolerance of rehab loading.
Week 8: functional gains — improved ROM, return to sub-maximal loading, reduced analgesic use. US may show improved fibrillar pattern.
Week 12: structural plateau; 60–75% of compliant patients return to sport or full ADLs.
Chronic cases lag this timeline by 2–4 weeks; acute injuries may respond within 2–3 weeks.
Injection site reactions (erythema, bruising, mild stinging) are common but self-limited.
Non-responders (~15–25%) should prompt reassessment of diagnosis, biomechanics, or metabolic/endocrine drivers.
Peptides accelerate biology — they do not replace progressive loading and structured rehabilitation.
Side Effects & Safety
- Injection site erythema, bruising, transient stinging
- Transient fatigue or flu-like malaise in first 1–2 weeks of TB-500
- Mild lightheadedness or flushing with BPC-157 (vasodilatory)
- Altered taste sensation (rare)
- Mild GI changes — nausea, altered bowel habits
- Theoretical concern regarding angiogenesis in undiagnosed malignancy
When to Stop & Call Provider
- New or rapidly enlarging mass or lymphadenopathy
- Unexplained bleeding, bruising, or hematuria
- Vision changes or new floaters (proliferative retinopathy concern)
- Severe or persistent injection site reaction or systemic allergic symptoms
- Pregnancy or planned conception
- New cancer diagnosis or recurrence
References
Sikiric et al. — BPC-157 in Tendon, Ligament, and Muscle Healing (preclinical series)
Robust mechanistic and preclinical literature demonstrating accelerated tendon, ligament, muscle, and GI healing with BPC-157, including VEGFR2-mediated angiogenesis and growth hormone receptor upregulation in tenocytes.
RegeneRx Thymosin Beta-4 Clinical Trials — Cardiac and Corneal Repair
Strongest human data for Thymosin Beta-4 exists in cardiac and corneal repair contexts. MSK use is largely extrapolated from this human safety data plus veterinary equine tendon literature.
Equine Tendon Repair with TB-500 — Veterinary Literature
Equine studies demonstrate accelerated superficial digital flexor tendon healing with TB-500, providing the strongest large-mammal evidence base for MSK applications.
Mechanistic Reviews — Thymosin Beta-4 Actin Sequestration & Stem Cell Mobilization
Reviews of G-actin sequestration, laminin-5 upregulation, anti-inflammatory cytokine modulation (TNF-α, IL-1β suppression), and endothelial progenitor cell recruitment supporting tissue repair.